| Attribute |
Value |
| 52 Week Change |
-0.635468 |
| Address1 |
3,655 Nobel Drive |
| Address2 |
Suite 260 |
| All Time High |
1,304.4 |
| All Time Low |
0.69 |
| Ask |
1.09 |
| Ask Size |
2 |
| Average Analyst Rating |
1.3 - Strong Buy |
| Average Daily Volume10 Day |
109,710 |
| Average Daily Volume3 Month |
522,962 |
| Average Volume |
522,962 |
| Average Volume10Days |
109,710 |
| Beta |
1.009 |
| Bid |
0.6086 |
| Bid Size |
2 |
| Book Value |
-0.037 |
| City |
San Diego |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.74 |
| Current Ratio |
0.986 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
0.7462 |
| Day Low |
0.7204 |
| Display Name |
Daré Bioscience |
| Dividend Date |
1,500,508,800 |
| Dividend Yield |
0.0 |
| Earnings Call Timestamp End |
1,786,653,000 |
| Earnings Call Timestamp Start |
1,786,653,000 |
| Earnings Timestamp |
1,786,651,200 |
| Earnings Timestamp End |
1,794,513,600 |
| Earnings Timestamp Start |
1,794,513,600 |
| Ebitda |
-8,978,829 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.608 |
| Enterprise To Revenue |
3.998 |
| Enterprise Value |
5,461,022 |
| Eps Current Year |
-0.77333 |
| Eps Forward |
-0.415 |
| Eps Trailing Twelve Months |
-0.71 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
0.84986 |
| Fifty Day Average Change |
-0.10986 |
| Fifty Day Average Change Percent |
-0.12926835 |
| Fifty Two Week Change Percent |
-63.5468 |
| Fifty Two Week High |
3.78 |
| Fifty Two Week High Change |
-3.04 |
| Fifty Two Week High Change Percent |
-0.8042328 |
| Fifty Two Week Low |
0.69 |
| Fifty Two Week Low Change |
0.050000012 |
| Fifty Two Week Low Change Percent |
0.07246379 |
| Fifty Two Week Range |
0.69 - 3.78 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,397,136,600,000 |
| Float Shares |
13,496,961 |
| Forward Eps |
-0.415 |
| Forward P E |
-1.7831326 |
| Free Cashflow |
-6,908,168 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
21 |
| Fullday Change |
0.011000037 |
| Fullday Change Percent |
1.5089215 |
| Fullday Price |
0.74 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
2.43908 |
| Gross Profits |
3,331,641 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.11724 |
| Held Percent Institutions |
0.13369 |
| Implied Shares Outstanding |
19,669,083 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,719,792,000 |
| Last Split Factor |
1:12 |
| Long Business Summary |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California. |
| Long Name |
Daré Bioscience, Inc. |
| Market |
us_market |
| Market Cap |
14,555,122 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_423979060 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-10,987,146 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
15,931,957 |
| Number Of Analyst Opinions |
3 |
| Open |
0.73 |
| Operating Cashflow |
-11,293,561 |
| Operating Margins |
-15.82534 |
| Payout Ratio |
0.0 |
| Phone |
858 926 7655 |
| Previous Close |
0.729 |
| Price Eps Current Year |
-0.9569007 |
| Price Hint |
4 |
| Price To Book |
-20.0 |
| Price To Sales Trailing12 Months |
10.655763 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.749 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.33333 |
| Region |
US |
| Regular Market Change |
0.011 |
| Regular Market Change Percent |
1.50892 |
| Regular Market Day High |
0.7462 |
| Regular Market Day Low |
0.7204 |
| Regular Market Day Range |
0.7204 - 0.7462 |
| Regular Market Open |
0.73 |
| Regular Market Previous Close |
0.729 |
| Regular Market Price |
0.74 |
| Regular Market Time |
1,792,094,401 |
| Regular Market Volume |
96,944 |
| Return On Assets |
-0.39286998 |
| Revenue Per Share |
0.097 |
| Sand P52 Week Change |
0.16207206 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
19,669,083 |
| Shares Percent Shares Out |
0.0469 |
| Shares Short |
922,037 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
976,672 |
| Short Name |
Dare Bioscience, Inc. |
| Short Percent Of Float |
0.0471 |
| Short Ratio |
3.03 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
DARE |
| Target High Price |
12.0 |
| Target Low Price |
5.0 |
| Target Mean Price |
8.33333 |
| Target Median Price |
8.0 |
| Total Cash |
12,617,594 |
| Total Cash Per Share |
0.825 |
| Total Debt |
6,763,626 |
| Total Revenue |
1,365,939 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.71 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.651665 |
| Two Hundred Day Average Change |
-0.91166496 |
| Two Hundred Day Average Change Percent |
-0.55196726 |
| Type Disp |
Equity |
| Volume |
96,944 |
| Website |
https://darebioscience.com |
| Zip |
92,122 |